Bayer Aktiengesellschaft (ETR:BAYN)
| Market Cap | 38.20B |
| Revenue (ttm) | 45.87B |
| Net Income (ttm) | -198.00M |
| Shares Out | 982.42M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | 9.72 |
| Dividend | 0.11 (0.28%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 3,533,159 |
| Average Volume | 3,508,986 |
| Open | 39.23 |
| Previous Close | 39.54 |
| Day's Range | 38.69 - 39.35 |
| 52-Week Range | 18.38 - 40.00 |
| Beta | 0.89 |
| RSI | 72.17 |
| Earnings Date | Feb 25, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
Bayer and Soufflé Therapeutics, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to ...
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration...
Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization
Cradle provides a scientific AI software platform focused on protein engineering Bayer continues to utilize AI in R&D, reinforcing commitment to modernize and scale its drug discovery and development ...
Bayer sues COVID vaccine makers over mRNA technology
Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ...
Pesticide industry ‘immunity shield’ stripped from US appropriations bill
Democrats and the Make America Healthy Again movement pushed back on the rider in a funding bill led by Bayer In a setback for the pesticide industry, Democrats have succeeded in removing a rider from...
Bayer-Krebsmittel Sevabertinib in USA und China mit Breakthrough-Therapy-Status
DJ Bayer-Krebsmittel Sevabertinib in USA und China mit Breakthrough-Therapy-Status DOW JONES--Bayer hat für sein Krebsmedikament Sevabertinib von den Zulassungsbehörden in den USA und China den St...
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan's 44th Annual Healthcare Conference
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board o...
BAYRY's 2025 Revival: Will the Momentum Continue in 2026?
BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.
Bayer: Is This The Turning Point Investors Have Been Waiting For?
DCM Shriram shares rally sharply 6% as company signs strategic MoU with Bayer to boost agri-innovation
DCM Shriram shares surged more than 6% after the company announced a strategic Memorandum of Understanding (MoU) with Bayer Crop...
DCM Shriram and Bayer Crop Science sign strategic MoU to advance sustainable agriculture in India
DCM Shriram Limited and Bayer Crop Science Limited have entered into a strategic Memorandum of Understanding (MoU) aimed at advancing...
EQS-News: Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
EQS-News: IBM / Key word(s): Product Launch Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis 05.12.2025 / 09:05 CET/CEST The issuer is solely responsible for the co...
Tandem Global e.V. Announces New Supervisory Board Members From AECOM, Bayer, and CRH
Trio joins Dow's Dr. Jihane Ball to provide critical guidance to the organisation's European initiatives MUNICH, DE / ACCESS Newswire / December 4, 2025 / Tandem Global, e.V., the European entity o...
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Evotec & Bayer Launch Phase 2 Trial for Alport Syndrome Treatment
Bayer and Evotec are advancing a new hope for Alport syndrome, testing a targeted antibody in a rigorous Phase 2 trial to improve outcomes for young adults.
EQS-News: Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome 04.12.2025 / 08:30 CET/CEST The issuer is solely responsible f...
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A ...
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-base...
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigati...
Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study
Bayer (BAYRY) Achieves Milestone with Pediatric MRI Contrast Agent Study
Bayer releases data for contrast agent gadoquatrane in children
Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit
Bayer (BAYN) Stock Surges Following DOJ Support in Roundup Lawsuit
Bayer Welcomes Solicitor General Support In Supreme Court Review Of Roundup Case
(RTTNews) - Bayer (BAYN.DE) Tuesday said it is "pleased" by the U.S. Solicitor General's support for Supreme Court review of its petition in the Durnell case, calling the government's backing a signif...
Here's Why the Maker of Roundup Weed Killer's Stock Is Surging Today
Shares of Bayer are surging on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review rulings on whether Roundup weed killer, produced b...